Seigerman added that Mirati has expressed interest to commercialise on its own, but "we think an acquisition by a larger biopharma name with experience in commercialising oncology assets could be ...

The drugmaker sees additional growth opportunities in ophthalmology and neuromuscular disorders, Chief Medical Officer Tadaaki Taniguchi said.

Lastly, the Mirati Therapeutics acquisition intensified targeted oncology assets to Bristol-Myers Squibb’s oncology portfolio, considerably diversifying it. Focusing on advancing its healthcare ...

Mirati – which is expecting a verdict on adagrasib from the FDA in December - also said the disease control rate was 80% with adagrasib, while the median duration of response came in at 8.5 ...